Tumor cells elicit immunogenic responses due to “hot spot” mutant p53 epitopes (neoantigens) produced via proteasomal degradation of intracellular protein and presented by major histocompatibility complex (MHC) (Figure 2A). This evidence concerns the gene TP53 and neoplasm.